ASH 2023: Ibrutinib/Venetoclax Superior to Fludarabine, Cyclophosphamide, Rituximab for Untreated CLL
Duration of treatment depends on measurable residual disease measurements
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.